Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 protein, crucial for genome integrity, is often inactivated in human cancers.
• In tumors with wild-type p53, its function is suppressed by overexpressed MDM2 and MDMX proteins.
• Existing MDM2 inhibitors are ineffective against MDMX, limiting their therapeutic potential.

Purpose of the Study:

• To discover novel dual-inhibitors targeting both MDM2 and MDMX proteins.
• To overcome the limitations of current inhibitors in tumors overexpressing MDMX.
• To develop compounds capable of reactivating the p53 pathway in cancer cells.

Main Methods:

• Utilized the relaxed complex scheme (RCS) for flexible receptor modeling in virtual screening.
• Screened compound libraries (NCI diversity set, DrugBank, derivative library) against multiple MDM2 conformations.
• Validated top MDM2 inhibitor candidates against the MDMX binding site.

Main Results:

• Identified a set of compounds predicted to inhibit both MDM2 and MDMX.
• These compounds demonstrated potential for dual antagonism of p53 regulators.
• Computational predictions suggest these inhibitors can activate the p53 pathway.

Conclusions:

• The study presents a computational strategy for identifying dual-inhibitors of MDM2 and MDMX.
• The identified compounds offer a promising avenue for reactivating p53 in wild-type p53 tumors.
• This research could lead to new cancer therapies targeting the p53 pathway.